Lorem Ipsm Dolor

These Analysts Revise Their Forecasts On Evolent Well being After Upbeat Outcomes – Evolent Well being (NYSE:EVH)

Evolent Well being, Inc. EVH reported better-than-expected fourth-quarter outcomes on Thursday.

Evolent Well being posted quarterly earnings of 23 cents per share, beating market estimates of 15 cents per share. The corporateā€™s quarterly gross sales got here in at $556.05 million versus market expectations of $542.39 million, based on information from Benzinga Professional.

Seth Blackley, Chief Govt Officer, and Co-Founding father of Evolent said, “We ended 2023 on a powerful word, reaching all of our monetary aims for the 12 months. Annual income elevated over 45% whereas we continued to ship sturdy earnings, pushed by continued underlying development in addition to the profitable integration of NIA. I’m extremely happy with our world crew who labored so onerous to collectively ship what we promised to each shareholders and companions in 2023. Our monetary place is powerful as money move exceeded our goal for the 12 months and we considerably improved our money and steadiness sheet flexibility.”

Evolent Well being shares gained 11.5% to commerce at $33.20 on Friday.

These analysts made adjustments to their value targets on Evolent Well being after the corporate reportedĀ outcomes for the current quarter.

  • Canaccord Genuity reduce the worth goal on Evolent Well being from $47 to $45. Canaccord Genuity analyst Richard Shut maintained a Purchase score.
  • JMP Securities raised the worth goal on Evolent Well being from $37 to $38. JMP Securities analyst Constantine Davides maintained a Market Outperform score.


Additionally Test This Out: Jim Cramer: Unity Software program ‘Had Issues,’ However Zscaler Is A ‘Good One’ To Purchase

Leave a Comment

Refund Reason